Global Flu Diagnostic And Treatment Market Size, Share, Opportunities, And Trends By Type Of Flu (Type A, Type B), By Offering (Diagnostics (Rapid Influenza Diagnostic Test, Rapid Molecular Assay, Others), Therapeutics), By Age Group (0-14 Years, 15-64 Years, >=65 Years), By End-User (Hospital Laboratory, Outpatient Clinic, Reference Laboratory), And By Geography - Forecasts From 2025 To 2030

Flu Diagnostic And Treatment Market Size:

The Global Flu Diagnostic And Treatment Market is expected to grow from USD 42.719 billion in 2025 to USD 61.342 billion in 2030, at a CAGR of 7.50%.

The global flu diagnostic and treatment market is poised to surge at a notable rate throughout the forecast period, majorly on account of the high prevalence of flu throughout the globe. The rising investments in R&D by key market players in the expansion of product lines and especially for improving the quality of products for the betterment of health is also expected to propel the growth opportunities for the market to surge during the forecast period and beyond.

In addition, the rising geriatric population throughout the globe, especially in countries like Japan, Italy, and Germany, among others, along with the presence of well-established healthcare systems in these countries, is also bolstering the flu diagnostic and treatment market growth during the next five years. Older people need more care and better health facilities as they are more prone to flu due to a weak immune system. The need for quality flu diagnosis and treatment is greater for the elderly; this has further increased the demand for flu diagnostic and treatment kits. According to the World Bank data, the population aged 65 and above of the total population has increased from 7.49% of the total population in the world in the year 2009 to 8.87% of the total world population in the year 2018. Influenza is considered a communicable and highly contagious disease. However, the disease is characterized by a sudden onset of sore throat, muscle and joint pain, dry cough, and fever. However, recovery without intensive medical attention is possible, but, in some cases, this may lead to severe illness and sometimes leads to death, especially in the high-risk population, which primarily includes pregnant women, aged people, infants, and people with immunosuppressive conditions.

Flu Diagnostic And Treatment Market Growth Factors:

• The rising prevalence of influenza across the globe is significantly driving the market growth

The high prevalence of influenza around the globe, coupled with the rising prevalence of influenza in numerous countries due to the non-availability of proper healthcare services and facilities, is one of the prime factors driving the market growth for the coming five years. Furthermore, according to the World Health Organisation (WHO), North America saw a rise in influenza activity with the majority of people infected with influenza A viruses, with at least 80% of adult influenza-associated hospitalizations being associated with influenza A viruses. The rise in influenza cases around the world is increasing the use of flu diagnostics and treatment to improve the health of people.

The growing prevalence of flu in many countries across the European and Asia Pacific region is also propelling the market growth during the next five years.

• Type A flu to rule the market

On the basis of the type of flu, the global flu diagnostic and treatment market has been classified into Type A and Type B viruses. The flu diagnostic and treatment market for type A virus is anticipated to hold a major market share throughout the forecast period as type A viruses are the most common flu virus that is diagnosed in many countries across the world. Similarly, the number of clinically diagnosed cases along with the number of hospitalizations with type A flu is also considerably higher than the type B segment. 

The type B flu segment is projected to hold a low share of the market as its incidence is comparatively lower than type A flu. However, the incidence of type B flu is growing, especially throughout the APAC region, which is considered one of the prime factors bolstering the growth of this segment over the forecast period.

• Outpatient clinics are expected to show notable growth during the next five years

On the basis of end-user, the global flu diagnostic and treatment market has been classified into hospital laboratories, outpatient clinics, and reference laboratories. The outpatient clinics segment is anticipated to show decent growth during the next five years as these healthcare settings offer point-of-care treatments at comparatively low costs. The hospital laboratory segment is projected to hold a significant share in the global flu diagnostic and treatment market during the next five years as hospitals offer long-term care facilities and are considered more reliable than other end-users.

Flu Diagnostic And Treatment Market Geographical Outlook:

• Asia Pacific region to show robust growth

The flu diagnostic and treatment market has been divided into five regions: North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The Asia Pacific region is anticipated to show robust growth throughout the forecast period owing to the fact that there is an increasing prevalence of influenza in major countries of the region, such as India, China, and Indonesia, among others, coupled with rising healthcare expenditure, especially in the developing countries. The North American region is projected to hold a noteworthy market share on account of the availability of a well-established healthcare sector in countries like the U.S and Canada along with high healthcare spending. All these factors together support the noteworthy share of North America in the global flu diagnostic and treatment market throughout the forecast period.

Global Flu Diagnostic and Treatment Market Segmentation:

• By Type of Flu
  • Type A
  • Type B
  • Others
• By Offering
  • Diagnostics
    • Rapid Influenza Diagnostic Test
    • Rapid Molecular Assay
    • RT-PCR & NAATs
    • Immunofluorescence Assays
    • At-Home Flu Testing Kits
  • Therapeutics
    • Antiviral Medications
    • Vaccines
    • Others
• By Age Group
  • 0-14 Years
  • 15-64 Years
  • >=65 Years
• By Mode of Administration
  • Oral
  • Intranasal
  • Injectable
• By End-User
  • Hospitals & Hospital Laboratories
  • Outpatient Clinic
  • Pharmacies & Retail Clinics
  • Reference Laboratories
  • Home Care/Self-Test Users
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Spain
    • Italy
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • Israel
    • UAE
    • Other
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Thailand
    • Indonesia
    • Taiwan
    • Others

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations

3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY TYPE OF FLU

5.1. Introduction

5.2. Type A

5.3. Type B

5.4. Others

6. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY OFFERING

6.1. Introduction

6.2. Diagnostics

6.2.1. Rapid Influenza Diagnostic Test

6.2.2. Rapid Molecular Assay

6.2.3. RT-PCR & NAATs

6.2.4. Immunofluorescence Assays

6.2.5. At-Home Flu Testing Kits

6.3. Therapeutics

6.3.1. Antiviral Medications

6.3.2. Vaccines

6.3.3. Others

7. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY AGE GROUP

7.1. Introduction

7.2. 0–14 Years

7.3. 15–64 Years

7.4. ≥65 Years

8. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY MODE OF ADMINISTRATION

8.1. Introduction

8.2. Oral

8.3. Intranasal

8.4. Injectable

9. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY END-USER

9.1. Introduction

9.2. Hospitals & Hospital Laboratories

9.3. Outpatient Clinic

9.4. Pharmacies & Retail Clinics

9.5. Reference Laboratories

9.6. Home Care/Self-Test Users

10. GLOBAL FLU DIAGNOSTIC AND TREATMENT MARKET BY GEOGRAPHY

10.1. Introduction

10.2. North America

10.2.1. USA

10.2.2. Canada

10.2.3. Mexico

10.3. South America

10.3.1. Brazil

10.3.2. Argentina

10.3.3. Others

10.4. Europe

10.4.1. Germany

10.4.2. France

10.4.3. United Kingdom

10.4.4. Spain

10.4.5. Others

10.5. Middle East and Africa

10.5.1. Saudi Arabia

10.5.2. UAE

10.5.3. Others

10.6. Asia Pacific

10.6.1. China

10.6.2. India

10.6.3. Japan

10.6.4. South Korea

10.6.5. Indonesia

10.6.6. Thailand

10.6.7. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

10.1. Major Players and Strategy Analysis

10.2. Market Share Analysis

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Competitive Dashboard

11. COMPANY PROFILES

11.1. QuidelOrtho Corporation

11.2. F. Hoffmann-La Roche AG

11.3. Becton, Dickinson and Company

11.4. Thermo Fisher Scientific Inc.

11.5. SA Scientific, Ltd.

11.6. Sekisui Diagnostics, LLC

11.7. Meridian Bioscience, Inc.

11.8. Oxford Biosystems Ltd.

11.9. Pfizer Inc.

11.10. Bayer AG

11.11. GlaxoSmithKline plc

11.12. Abbott Laboratories

11.13. Danaher Corporation

11.14. Sanofi S.A.

11.15. Hologic, Inc.

11.16. Luminex Corporation

11.17. DiaSorin S.p.A.

12. APPENDIX

12.1. Currency

12.2. Assumptions

12.3. Base and Forecast Years Timeline

12.4. Key Benefits for the Stakeholders

12.5. Research Methodology

12.6. Abbreviations

QuidelOrtho Corporation

F. Hoffmann-La Roche AG

Becton, Dickinson and Company

Thermo Fisher Scientific Inc.

SA Scientific, Ltd.

Sekisui Diagnostics, LLC

Meridian Bioscience, Inc.

Oxford Biosystems Ltd.

Pfizer Inc.

Bayer AG

GlaxoSmithKline plc

Abbott Laboratories

Danaher Corporation

Sanofi S.A.

Hologic, Inc.

Luminex Corporation

DiaSorin S.p.A.